Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS From ASH"

By Insights from 2023 ASH Annual Meeting FEATURING Rahul Banerjee
By Insights from 2023 ASH Annual Meeting FEATURING Rahul Banerjee
870 views
January 31, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Recommended

17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views

·

7 months ago
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views

·

10 months ago
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

616 views

·

4 months ago
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

631 views

·

4 months ago
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

135 views

·

2 months ago
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

368 views

·

3 months ago
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

619 views

·

5 months ago
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views

·

4 months ago
15:46

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

402 views

·

3 months ago
07:11

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

2.0K views

·

1 year ago
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

883 views

·

7 months ago
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

465 views

·

8 months ago
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

466 views

·

4 months ago
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

414 views

·

1 month ago
13:47

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

395 views

·

5 months ago
22:33

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

208 views

·

3 months ago
09:07

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

205 views

·

1 month ago
26:46

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

Samer Al Hadidi

599 views

·

7 months ago
05:35

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

Saurabh Chhabra

382 views

·

7 months ago
20:18

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

505 views

·

8 months ago
AUTOPLAY